Cardiorenal end points in a trial of aliskiren for type 2 diabetes.
By H. Parving, B. Brenner, J. McMurray, D. de Zeeuw, S. Haffner, S. Solomon, N. Chaturvedi, F. Persson, Akshay S. Desai, M. Nicolaides and 4 more. 2012
1,215 citations recorded by the source corpus.
Subfields: Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cardiology and Cardiovascular Medicine
In Endocrinology, Diabetes and Metabolism
Citations in the corpus
- Modeling polypharmacy side effects with graph convolutional networks (2018, background): “…approach for multirelational link prediction in any multimodal network, it would be interesting to apply it to other domains andproblems, forexample, findingassociationsbetweenpatientoutcomes and comorbid diseases, or for identifying dependencies between mutant phenotypes and gene-gene interactions.”
- Guidelines for the Primary Prevention of Stroke (2011, neutral): “The results of a recent trial of the direct renin inhibitor aliskiren in patients with type 2 diabetes mellitus plus chronic kidney disease or prevalent CVD did not find evidence that aliskiren reduced cardiovascular end points, including stroke.(241) In general, therefore, although the benefits of ”
- Diabetes and Hypertension: A Position Statement by the American Diabetes Association (2017, background): “Also, in volume depleted states, risk for hyperkalemia increases (71,72,88).”